ALK-positive Advanced NSCLC clinical trials at UC Health
1 in progress, 1 open to new patients
open to eligible people ages 18 years and up
The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum tolerated dose . The Dose Expansion Phase will explore the safety, tolerability, and anti-tumor activity of the combination.